HRSA refers 6 drug firms to OIG for 340B noncompliance


Six drugmakers -- Sanofi, AstraZeneca, Novartis, Eli Lilly, Novo Nordisk and United Therapeutics -- received letters from HHS' Health Resources and Services Administration warning that they may face up to $5,000 in fines for refusing to provide 340B discounts to hospitals. The HRSA referred the drugmakers to the HHS Office of Inspector General, which will decide whether the firms should be fined for deliberately overcharging 340B hospitals.

Full story:

FDLI SmartBrief

The latest regulatory and company news on food, drugs, animal drugs, biologics, cosmetics, diagnostics, dietary supplements, medical devices and tobacco

Designed specifically for professionals involved in the food and drug law community, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition.